We were the first lupus organization in the U.S. to support stromal cell research. In partnership with the National Institute of Allergy and Infectious Diseases, we committed nearly $4 million over ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first mesenchymal stromal cell ...

The contribution of molecular alterations in bone marrow mesenchymal stromal cells (BM-MSC) to the pathogenesis of acute myeloid leukemia (AML) is poorly understood. Thus we assessed genome-wide ...

December 2024, immediately following the approval of the world's first mesenchymal stromal cells clinical trial, the U.S. FDA ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Honey isn't just for sweetening your tea—it’s a skincare powerhouse! 🍯 Guerlain’s new Abeille Royale Youth Watery Oil Serum ...

Mandates Ryoncil® CoverageNEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that ...

Preliminary work by Farmer and Wang proved that prenatal surgery combined with human placenta-derived mesenchymal stromal cells, held in place with a biomaterial scaffold to form a “patch ...

Mesoblast’s flagship product, RYONCIL, is the first FDA-approved mesenchymal stromal cell therapy for treating ...

the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States. We have been engaging ...